FDA’s Rare Disease Evidence Principles (RDEP): Use Real-World Evidence in Ultra-Rare Drug Development
IQVIA2026-01-237 页
GENERAL CONSIDERATIONS FOR PATIENT PREFERENCE STUDIES (E22)
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)2026-02-0319 页
Q4 2025 Pharma Services Report
PitchBook2026-03-267 页
Annual Completed Clinical Trials Report
Citeline (Pharma Intelligence UK Limited)2026-07-1538 页